Nine Masts Capital »

Prelude Therapeutics shares owned by Nine Masts Capital

Quarter-by-quarter ownership of Prelude Therapeutics (PRLD) shares owned by Nine Masts Capital from 13F filings

Historical chart of Nine Masts Capital investment in Prelude Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Prelude Therapeutics held by Nine Masts Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Prelude Therapeutics by Nine Masts Capital

Quarter filed Position value Share count Share price at filing
2026-03-31 $40k 12k 3.42

More positions owned by Nine Masts Capital

State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Alibaba Group Hldg Note 0.500% 6/0 (Principal)
Alphabet Cap Stk Cl C (GOOG)
Warner Bros Discovery Com Ser A (WBD)
Silicon Laboratories (SLAB)
Hdfc Bank Sponsored Ads (HDB)
Electronic Arts (EA)
Fox Corp Cl B Com (FOX)
Norfolk Southern (NSC)
Clearwater Analytics Hldgs I Cl A (CWAN)
Webster Financial Corporation (WBS)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Hologic
Nio Note 4.625%10/1 (Principal)
Ase Technology Hldg Sponsored Ads (ASX)

View all positions for Nine Masts Capital

Top funds holding Prelude Therapeutics

OrbiMed Advisors
Baker Bros. Advisors
Kynam Capital Management
Vanguard Group
Vanguard Capital Management
EcoR1 Capital
Two Sigma Investments
Sphera Funds Management
Acadian Asset Management
Millennium Management
Morgan Stanley
BlackRock
Geode Capital Management
Marshall Wace
Renaissance Technologies

View all funds holding Prelude Therapeutics